Description of Invention: Inherited prostate cancer susceptibility genes with high penetrance are responsible for 5% to 10% of all cancer cases and up to 30% to 40% of early onset of the disease. Previous genetic linkage studies indicated that germline variations in a gene or genes on Xq27 were involved in prostate carcinogenesis. The linkage peak for prostate cancer overlies a region containing five SPANX genes whose expression has been detected in a variety of cancers. The investigators have identified an intra-chromosomal inversion involving more than a 400 kb sequence in prostate cancer patients but not in unaffected individuals. This technology can be used as an accurate, early prostate cancer susceptibility diagnostics method.
Applications: High throughput screening assay to predict patient susceptibility to prostate cancer
Advantages: Easy, ready to use early stage prostate cancer diagnostic
Development Status: The technology is currently in the pre-clinical stage of development.
Inventors: Natalay Kouprina (NCI)
Licensing Status: Available for licensing.
Portfolios: Cancer Cancer - Diagnostics Gene Based Therapies Gene Based Therapies - Diagnostics
For Additional Information Please Contact: Jennifer Wong NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: wongje@mail.nih.gov Phone: 301-435-4633 Fax: 301-402-0220
Description of Invention:
Inherited prostate cancer susceptibility genes with high penetrance are responsible for 5% to 10% of all cancer cases and up to 30% to 40% of early onset of the disease. Previous genetic linkage studies indicated that germline variations in a gene or genes on Xq27 were involved in prostate carcinogenesis. The linkage peak for prostate cancer overlies a region containing five SPANX genes whose expression has been detected in a variety of cancers. The investigators have identified an intra-chromosomal inversion involving more than a 400 kb sequence in prostate cancer patients but not in unaffected individuals. This technology can be used as an accurate, early prostate cancer susceptibility diagnostics method.
Applications:
High throughput screening assay to predict patient susceptibility to prostate cancer
Advantages:
Easy, ready to use early stage prostate cancer diagnostic
Development Status:
The technology is currently in the pre-clinical stage of development.
Inventors:
Natalay Kouprina (NCI)
Licensing Status:
Available for licensing.
Portfolios:
Cancer
Cancer - Diagnostics
Gene Based Therapies
Gene Based Therapies - Diagnostics
For Additional Information Please Contact:
Jennifer Wong
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: wongje@mail.nih.gov
Phone: 301-435-4633
Fax: 301-402-0220
Ref No: 1857
Updated: 12/2008